Hematologic Oncology

Craig Moskowitz, MD, physician-in-chief, Oncology Service Line, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of PET-adapted therapy in the treatment of patients with advanced-stage Hodgkin lymphoma.

The optimal anticoagulant takes into consideration a variety of components, including patient preference, the indication for anticoagulation, comorbidities, reversibility, and other factors relevant to the clinical scenario.

The R2 regimen of lenalidomide plus rituximab significantly reduced the risk of disease progression or death compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma, according to results from the pivotal phase III AUGMENT trial.

A supplemental biologics license application has been submitted to the FDA for luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndrome–associated anemia with ring sideroblasts who require red blood cell transfusions, and also for adult patients with beta-thalassemia–associated anemia who require such transfusions.

Alvaro Jose Alencar, MD, highlights advances made in the treatment of patients with hematologic disorders, offers advice on how to choose between available agents, and sheds light on future research.

Paul J. Shaughnessy, MD, medical director of adult blood and marrow transplant at the Texas Transplant Institute, discusses unanswered questions in the field of diffuse large B-cell lymphoma (DLBCL).

Kidney complications often occur following successful hematopoietic stem cell transplantation from a myriad of underlying etiologies.

The FDA has added 3 months to the review period for a new drug application for quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia, allowing the agency to review additional data provided by Daiichi Sankyo.

Terrence J. Bradley, MD, discusses approved and investigational agents that patients with myelofibrosis and polycythemia vera can turn to.

While complex, criteria for diagnosing transplant-associated thrombotic microangiopathy following hematopoietic stem cell transplantation should be closely followed and should begin with screening.

Cyclophosphamide administered alone or in combination with other agents is an effective prophylactic treatment for graft-versus-host disease, regardless of stem cell source, conditioning intensity, or patient age in 10/10 and 9/10 human leukocyte antigen matched unrelated donor hematopoietic stem cell transplantation recipients.

The development of high-grade acute graft-versus-host disease following hematopoietic stem cell transplantation poses the highest risk for transplant-associated thrombotic microangiopathy in pediatric patients.

Patients with multiple myeloma who relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies demonstrated a strong response to daratumumab salvage therapy.

James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses anticipated developments in the field of multiple myeloma.

Gilteritinib was found to significantly improve overall survival in patients with relapsed/refractory FLT3 mutation–positive acute myeloid leukemia, according to updated findings of the phase III ADMIRAL trial.

The PI3K-delta inhibitor umbralisib was found to demonstrate an overall response rate of 52% and show an encouraging tolerability profile in patients with relapsed/refractory marginal zone lymphoma, according to findings from a cohort of the phase IIb UNITY-NHL trial.

A novel treatment of ruxolitinib combined with etanercept led to encouraging response and survival rates in patients who developed grades 3/4 steroid-resistant acute graph-versus-host disease after undergoing allogeneic stem cell transplantation.

Terrence J. Bradley, MD, assistant professor, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami in Health System, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms (MPNs).

Treosulfan added to fludarabine demonstrated an improvement in event-free and overall survival compared with busulfan/fludarabine as a treatment for patients with acute myeloid leukaemia or myelodysplastic syndrome who are scheduled for allogeneic hematopoietic stem cell transplantation but are considered ineligible for standard myeloablative conditioning.

The FDA has granted a breakthrough therapy designation to the combination of ivosidenib and azacitidine for the treatment of newly diagnosed patients with IDH1-mutant acute myeloid leukemia ≥75 years old or are ineligible for intensive induction chemotherapy.

Craig Moskowitz, MD, discusses the role of PET imaging in the treatment of patients with Hodgkin lymphoma, weighs the pros and cons of A+AVD, and speaks to where future research is headed in the space.

Justin M. Watts, MD, sheds light on these promising agents and their impact in the space, discusses remaining challenges, and expresses his hope for an era where most patients with acute myeloid leukemia will be cured.

Stephen D. Nimer, MD, sheds light on new strategies and trends in the treatment of patients with hematologic malignancies.

With careful monitoring, discontinuation of TKI therapy is considered safe in adult patients with chronic myeloid leukemia in the chronic phase, who achieve and maintain a major molecular response.

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses promising combinations in multiple myeloma.

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the emergence of bispecific T-cell engagers (BiTEs) in multiple myeloma.

FLT3 inhibition continues to be explored as a therapeutic option for patients with FLT3-mutant acute myeloid leukemia, with quizartinib at the forefront following intriguing results of the phase III QuANTUM-R trial.

Immune-based approaches have revolutionized the treatment of acute lymphoblastic lymphoma, especially for patients unable to tolerate multiagent chemotherapy. Now, investigators are looking forward to seeing these agents move into frontline settings, perhaps leading to chemotherapy-free approaches.

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses anticipated research in the field of multiple myeloma.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the management of early relapse in multiple myeloma.